Achieve Life Sciences, Inc.

NasdaqCM ACHV

Achieve Life Sciences, Inc. Market Capitalization on January 14, 2025: USD 108.33 M

Achieve Life Sciences, Inc. Market Capitalization is USD 108.33 M on January 14, 2025, a 1.66% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Achieve Life Sciences, Inc. 52-week high Market Capitalization is USD 188.94 M on June 04, 2024, which is 74.42% above the current Market Capitalization.
Achieve Life Sciences, Inc. 52-week low Market Capitalization is USD 95.78 M on February 22, 2024, which is -11.58% below the current Market Capitalization.
Achieve Life Sciences, Inc. average Market Capitalization for the last 52 weeks is USD 148.55 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: ACHV

Achieve Life Sciences, Inc.

CEO	Dr. Richard A. B. Stewart
IPO Date	Oct. 12, 1995
Location	Canada
Headquarters	1040 West Georgia Street
Employees	22
Sector	Health Care
Industries Pharmaceuticals Biotechnology Tobacco

Description

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Key trends

Past 5 years